NCT03338244View on ClinicalTrials.gov

Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

PHASE4CompletedINTERVENTIONAL
Enrollment

66,228

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Childhood Mortality
Interventions
DRUG

Azithromycin

Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months

DRUG

Placebo

Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months

Trial Locations (2)

94143-0944

UCSF Proctor Foundation, San Francisco

Unknown

The Carter Center, Niamey

All Listed Sponsors
collaborator

The Carter Center

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of California, San Francisco

OTHER

NCT03338244 - Mortality Reduction After Oral Azithromycin Contingency: Mortality Study | Biotech Hunter | Biotech Hunter